{
    "clinical_study": {
        "@rank": "84049", 
        "arm_group": {
            "arm_group_label": "Neoadjuvant Therapy", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the effect of Avastin (15mg/kg iv) in combination with Docetaxel\n      and Xeloda, given as pre-operative therapy to patients with primary breast cancer. Avastin\n      will be administered every 3 weeks, for the first 5 cycles of chemotherapy. The anticipated\n      time on study treatment is 3-12 months."
        }, 
        "brief_title": "A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer", 
        "completion_date": {
            "#text": "April 2008", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  female patients, 18-70years of age;\n\n          -  histologically-proven invasive breast cancer;\n\n          -  no prior or current neoplasm except for non-melanoma skin cancer, or in situ cancer\n             of the cervix;\n\n          -  no distant disease/secondary cancer.\n\n        Exclusion Criteria:\n\n          -  pregnant or lactating women;\n\n          -  pre-operative local treatment for breast cancer;\n\n          -  prior or concurrent systemic antitumor therapy;\n\n          -  clinically significant cardiac disease."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005549", 
            "org_study_id": "ML19869"
        }, 
        "intervention": [
            {
                "arm_group_label": "Neoadjuvant Therapy", 
                "description": "15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles", 
                "intervention_name": "bevacizumab [Avastin]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Neoadjuvant Therapy", 
                "description": "75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles", 
                "intervention_name": "docetaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Neoadjuvant Therapy", 
                "description": "950 mg/m2, orally twice daily, evening of Day 1 until morning of Day 15, followed by a 7 day rest period, every 3 weeks", 
                "intervention_name": "capecitabine [Xeloda]", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Capecitabine", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Salzburg", 
                    "country": "Austria", 
                    "zip": "5020"
                }
            }
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Bevacizumab With Docetaxel and Capecitabine in the Neoadjuvant Setting for Breast Cancer Patients", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Austria: Austrian Federal Office for Safety in Health Care"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Pathological complete response rate", 
            "safety_issue": "No", 
            "time_frame": "18 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005549"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinical objective response rate", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "Rate of breast-conserving surgery", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }, 
            {
                "measure": "Safety: Incidence of serious and specific adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2006", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}